Atlas Capital Advisors’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Atlas Capital Advisors’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-40,000	Closed	-$36.4K	–	976
2023 Q4	$36.4K	Hold	40,000	–	–	0.01%	629
2023 Q3	$36.4K	Buy	40,000 +15,000	+60%	+$63K	0.01%	571
2023 Q2	$96.3K	Hold	25,000	–	–	0.01%	479
2023 Q1	$75.5K	Hold	25,000	–	–	0.01%	508
2022 Q4	$51.3K	Hold	25,000	–	–	0.01%	537
2022 Q3	$86.5K	Hold	25,000	–	–	0.02%	466
2022 Q2	$105K	Sell	25,000 -16,025	-39%	-$37.9K	0.02%	453
2022 Q1	$125K	Hold	41,025	–	–	0.02%	440
2021 Q4	$191K	Hold	41,025	–	–	0.03%	364
2021 Q3	$316K	Buy	41,025 +23,227	+131%	+$177K	0.05%	270
2021 Q2	$153K	Buy	+17,798	New	+$157K	0.03%	394

Atlas Capital Advisors's DBTX Position: Q1 2024 in Review

Atlas Capital Advisors sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q1 2024, closing a stake of 40,000 shares — an estimated $36.4K sold.

Atlas Capital Advisors first reported a position in DBTX in Q2 2021 and held it in 11 quarters. The position peaked at $316K in Q3 2021. 0 funds tracked by Wall St. Rank hold DBTX as of Q1 2024.

Atlas Capital Advisors reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Atlas Capital Advisors sold 40,000 Decibel Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $36.4K.
Atlas Capital Advisors first reported a position in Decibel Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
Atlas Capital Advisors's Decibel Therapeutics, Inc. Common Stock position peaked at $316K in Q3 2021.
0 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Atlas Capital Advisors's 13F filing for Q1 2024, filed 15 Apr 2024.